07:00 , May 24, 2004 |  BioCentury  |  Strategy

Novartis finds its gold standard

With one antibody on the market and others in the clinic through partnerships, Novartis AG has a vested interest in this class of biologics. But until now, the company has had no internal capability in...
07:00 , May 10, 2004 |  BC Week In Review  |  Company News

Wilex management update

Wilex AG , Munich, Germany   Business: Cancer   Hired: Niels Ackermann as CFO, formerly CFO and acting co-CEO of Cardion AG ; he replaces Richard Chambers, who resigned  ...
08:00 , Feb 23, 2004 |  BioCentury  |  Finance

Ebb & Flow

Even when many companies continue to land big financing rounds, sometimes it's best to stop fishing for money. With one good deal in hand, investors in Cardion concluded that it was time to fold up...
08:00 , Jan 19, 2004 |  BC Week In Review  |  Company News

igeneon management update

igeneon AG , Vienna, Austria   Business: Cancer   Hired: Manfred Rüdiger as COO, formerly CSO of Cardion AG  ...
08:00 , Jan 12, 2004 |  BC Week In Review  |  Company News

igeneon management update

igeneon AG , Vienna, Austria   Business: Cancer   Hired: Manfred Rudiger as COO, formerly CSO at Cardion AG  ...
07:00 , Jul 28, 2003 |  BC Week In Review  |  Company News

Cardion, Roche deal

ROCZ will acquire Cardion's human interleukin IL-15 cytokine receptor blocker (CRB-15). The compound is in preclinical testing to treat rheumatoid arthritis and transplant rejection. ROCZ will be responsible for all development. Cardion will receive an...
07:00 , Jul 28, 2003 |  BioCentury  |  Product Development

Roche's product deal flow

Roche's product deal flow Date Partner Disease area Status at time of deal Deal 4/9/02 Isotechnika (TSE:ISA) Autoimmune/Inflammation, Transplant Ph II Will co-develop ISA's ISA247, a calcineurin inhibitor immunosuppressant in Phase II testing for renal...
07:00 , Jul 22, 2003 |  BC Extra  |  Company News

Roche acquires Cardion's CRB-15

Roche (SWX:ROCZ) will acquire Cardion's human interleukin IL-15 cytokine receptor blocker (CRB-15). The compound is in preclinical testing to treat rheumatoid arthritis and transplant rejection. ROCZ will be responsible for all development. Cardion (Ekrath, Germany)...
07:00 , May 12, 2003 |  BioCentury  |  Finance

Europe's top decile & quartile

Europe's top decile & quartile Company Aggregate raised (2000-1Q03) PharmaMar $173.3 Biovitrum $85.0 Cellzome $71.3 Strakan Group $65.7 Cytos $59.1 ProSkelia $58.4 RiboTargets $55.6 Micromet $51.5 Personal Chemistry $50.8 Morphochem $50.4 Cardion $48.6 Renovo $48.4...
08:00 , Feb 24, 2003 |  BC Week In Review  |  Company News

Cardion, Pfizer deal

PFE received a non-exclusive license to Cardion's Genomics Enabler technology which enables the production of pure populations of functional cell types. PFE may use the technology to facilitate drug screening, target gene validation and predictive...